Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
🎯 Clinical Bottom Line
In node-positive, HR+/HER2−, RS ≤25 breast cancer, adding chemotherapy to endocrine therapy did not significantly improve IDFS in the overall population. However, a significant interaction with menopausal status revealed two distinct stories: premenopausal women had a substantial chemotherapy benefit, while postmenopausal women had no benefit at all — regardless of recurrence score. This has fundamentally changed adjuvant decision-making by menopausal status.
Key Result (Overall): IDFS at 5 years — 92.2% vs 91.0%, HR 0.86 (95% CI 0.72–1.03; P=0.10) Key Result (Premenopausal): IDFS at 5 years — 93.9% vs 89.0%, HR 0.60 (95% CI 0.43–0.83; P=0.002) Key Result (Postmenopausal): IDFS at 5 years — 91.3% vs 91.9%, HR 1.02 (95% CI 0.82–1.26; P=0.89)
Safety Signal: No safety data reported in this publication.
✅ Patient Eligibility
Must Have:
- HR-positive, HER2-negative breast cancer
- 1–3 positive axillary lymph nodes (N1)
- Oncotype DX recurrence score 0–25
- Undergone primary surgery with SNB or ALND
Cannot Have:
- Distant metastasis
- Inflammatory breast cancer
- RS >25
💊 Dosing Quick Guide
Chemoendocrine Arm
Chemotherapy followed by endocrine therapy - Premenopausal preferred: anthracycline + taxane (54%) - Postmenopausal preferred: taxane + cyclophosphamide (57%) - Specific doses and schedules not reported in this publication
Endocrine-Only Arm
Endocrine therapy alone
- Specific agents, doses, and schedules not reported in this publication
No comparator drug was involved — the question was whether to add chemotherapy.
⚠️ Safety Snapshot
No safety data are reported in this publication. Toxicity data may be available in the supplementary appendix.
📊 Key Numbers
Median follow-up: 5.3 years
| Outcome (Population) | Chemoendocrine | Endocrine-Only | HR (95% CI) | p-value |
|---|---|---|---|---|
| IDFS 5-yr (Overall) | 92.2% | 91.0% | 0.86 (0.72–1.03) | P=0.10 |
| IDFS 5-yr (Postmeno) | 91.3% | 91.9% | 1.02 (0.82–1.26) | P=0.89 |
| IDFS 5-yr (Premeno) | 93.9% | 89.0% | 0.60 (0.43–0.83) | P=0.002 |
| DRFS 5-yr (Overall) | 94.9% | 93.9% | 0.88 (0.71–1.09) | P=0.25 |
| DRFS 5-yr (Postmeno) | 94.4% | 94.4% | 1.05 (0.81–1.37) | P=0.70 |
| DRFS 5-yr (Premeno) | 96.1% | 92.8% | 0.58 (0.39–0.87) | P=0.009 |
Treatment-by-menopausal status interaction: P=0.008
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| RxPONDER | Chemoendocrine vs endocrine | HR+/HER2−, N1, RS 0–25 | IDFS | Overall HR 0.86, P=0.10; Premeno HR 0.60, P=0.002 | [1] |
| TAILORx | Chemoendocrine vs endocrine | HR+/HER2−, N0, RS 11–25 | IDFS | See [4] | [4] |
| monarchE | Abemaciclib + ET vs ET | HR+/HER2−, N+, high risk | IDFS | See [5] | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Premenopausal Women
Age <45 yr: HR 0.49 (95% CI 0.28–0.84) — strong chemotherapy benefit Age 45–49 yr: HR 0.46 (95% CI 0.25–0.86) — strong chemotherapy benefit Age ≥50 yr: HR 0.98 (95% CI 0.54–1.78) — no apparent benefit (interaction P=0.06) RS 0–13: HR 0.49 (95% CI 0.24–0.99) — benefit even at lowest scores RS 14–25: HR 0.63 (95% CI 0.43–0.91) — benefit confirmed
Postmenopausal Women
RS 0–13: HR 1.01 (95% CI 0.71–1.44) — no benefit RS 14–25: HR 1.01 (95% CI 0.77–1.33) — no benefit 2–3 positive nodes: HR 1.22 (95% CI 0.87–1.71) — no benefit, even with higher nodal burden
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Oncotype DX cleared as prognostic/predictive assay; no separate drug approval from this trial [2] |
⚠️ Verify current regulatory status before prescribing.
NCCN: For postmenopausal women with N1 and RS ≤25: endocrine therapy alone recommended. For premenopausal women with N1 and RS ≤25: chemoendocrine therapy recommended [3].
⚡ Grey Zones
- Premenopausal chemotherapy benefit may be driven by ovarian suppression rather than cytotoxic effect — only 6.3% in the chemo arm vs 19.0% in the endocrine arm received prescribed ovarian suppression
- Premenopausal women ≥50 years showed no chemotherapy benefit (HR 0.98), but the interaction was not significant (P=0.06) — genuine clinical uncertainty
- Overall survival data are immature at 58% information fraction
- No safety data reported in this publication — toxicity burden unknown for this specific population
- 16.2% non-adherence in the chemoendocrine arm dilutes the ITT effect estimate
📖 Full Analysis
Read the complete desktop article with full efficacy tables, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Kalinsky K, Barlow WE, Gralow JR, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336-2347. doi:10.1056/NEJMoa2108873
- Oncotype DX Breast Recurrence Score test. Exact Sciences. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2026. Accessed March 2026.
- Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.
- Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998.